contrave and glp-1 Contrave (Naltrexone/Bupropion) For Weight Loss

compounded platforms offer greater dosing flexibility if clinically indicated

The phase 1b combination study by Enebo and colleagues, which examined multiple ascending doses of cagrilintide together with semaglutide 2.4 mg, characterized pharmacodynamic markers including appetite and gastrointestinal effects during the early weeks of dosing, before meaningful body-weight separation had emerged

doi:10.1097/MAO.0000000000000472 42

Meissner, W

For patients with coexisting type 2 diabetes or obesity, coordinate care between your endocrinologist and gastroenterologist to ensure treatment decisions consider both conditions

PMCID: PMC7037223 Khavinson VKh, Kuznik BI, Tarnovskaia SI, Lin'kova NS